Unknown × Myelodysplastic Syndromes × Other hematologic neoplasm × Clear all Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1 Unknown
24 enrolled
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Phase 1 Unknown
112 enrolled
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Phase 1 Unknown
198 enrolled
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Phase 1/2 Unknown
69 enrolled
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
Phase 1/2 Unknown
22 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase 1 Unknown
48 enrolled
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1 Unknown
32 enrolled
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1/2 Unknown
126 enrolled
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
Phase 2 Unknown
70 enrolled
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Phase 1/2 Unknown
120 enrolled
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase 1 Unknown
38 enrolled
Enhanced Palliative Care in MDS and AML
Phase NA Unknown
90 enrolled
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 Unknown
73 enrolled
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Phase 1/2 Unknown
20 enrolled
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1 Unknown
58 enrolled
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Phase 2/3 Unknown
180 enrolled
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Phase 1/2 Unknown
20 enrolled
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1/2 Unknown
100 enrolled
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Phase NA Unknown
300 enrolled
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Phase 1 Unknown
40 enrolled
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Phase 2 Unknown
5 enrolled
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Unknown
102 enrolled 12 charts
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Phase 2 Unknown
50 enrolled
CALVI
Phase 3 Unknown
140 enrolled
Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1/2 Unknown
5 enrolled
PRO-DLI
Phase 2 Unknown
124 enrolled
NK Cells in Cord Blood Transplantation
Phase 1 Unknown
13 enrolled
AML18
Phase 2/3 Unknown
1,600 enrolled
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
Unknown
191 enrolled
ToTem
Phase 1 Unknown
18 enrolled
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
Unknown
1,000 enrolled
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Phase 1/2 Unknown
65 enrolled
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
Phase 3 Unknown
100 enrolled
ProT4
Phase 2 Unknown
114 enrolled
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Phase 2 Unknown
40 enrolled
TRANSATRA
Phase 1/2 Unknown
60 enrolled
GREFFE
Unknown
150 enrolled
MacHaploMud
Phase 3 Unknown
344 enrolled
AML
Phase 1/2 Unknown
105 enrolled
PANOBEST
Phase 1/2 Unknown
62 enrolled
GLIDE
Phase 1/2 Unknown
20 enrolled
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
Phase 1 Unknown
10 enrolled
BBMPI03
Phase 1 Unknown
4 enrolled
PODAC
Phase 1 Unknown
19 enrolled
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
Phase NA Unknown
35 enrolled
GFM-Chimio-Rev
Phase 2 Unknown
85 enrolled
B-cell therapy
Phase 1/2 Unknown
15 enrolled
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Phase 2 Unknown
25 enrolled
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Phase 1/2 Unknown
16 enrolled